91 related articles for article (PubMed ID: 18846007)
1. CTLA4Ig and the therapeutic potential of T cell co-stimulation blockade.
Graca L
Acta Reumatol Port; 2008; 33(3):267-76. PubMed ID: 18846007
[TBL] [Abstract][Full Text] [Related]
2. T-cell agents in the treatment of rheumatoid arthritis.
Solomon GE
Bull NYU Hosp Jt Dis; 2010; 68(3):162-5. PubMed ID: 20969545
[TBL] [Abstract][Full Text] [Related]
3. Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis.
Korhonen R; Moilanen E
Basic Clin Pharmacol Toxicol; 2009 Apr; 104(4):276-84. PubMed ID: 19228144
[TBL] [Abstract][Full Text] [Related]
4. T-cell agents in the treatment of rheumatoid arthritis - 2011 update.
Solomon GE
Bull NYU Hosp Jt Dis; 2011; 69(3):230-2. PubMed ID: 22035434
[No Abstract] [Full Text] [Related]
5. New therapeutics that treat rheumatoid arthritis by blocking T-cell activation.
MacKenzie NM
Drug Discov Today; 2006 Oct; 11(19-20):952-6. PubMed ID: 16997147
[TBL] [Abstract][Full Text] [Related]
6. T-cell agents in the treatment of rheumatoid arthritis - 2012 update.
Solomon GE
Bull NYU Hosp Jt Dis; 2012; 70(3):191-4. PubMed ID: 23259627
[No Abstract] [Full Text] [Related]
7. [Abatacept in the treatment of active rheumatoid arthritis].
Nielsen H; Hansen A
Ugeskr Laeger; 2009 Jan; 171(4):214-7. PubMed ID: 19174034
[TBL] [Abstract][Full Text] [Related]
8. Co-stimulatory pathways controlling activation and peripheral tolerance of human CD4+CD28- T cells.
Park W; Weyand CM; Schmidt D; Goronzy JJ
Eur J Immunol; 1997 May; 27(5):1082-90. PubMed ID: 9174596
[TBL] [Abstract][Full Text] [Related]
9. Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade.
Manadan AM; Block JA
Am J Ther; 2008; 15(1):53-8. PubMed ID: 18223354
[TBL] [Abstract][Full Text] [Related]
10. CD4 and CD8 accessory molecules function through interactions with major histocompatibility complex molecules which are not directly associated with the T cell receptor-antigen complex.
Lustgarten J; Waks T; Eshhar Z
Eur J Immunol; 1991 Oct; 21(10):2507-15. PubMed ID: 1915555
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis.
Emery P
Expert Opin Investig Drugs; 2003 Apr; 12(4):673-81. PubMed ID: 12665422
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis.
Kremer JM
Rheum Dis Clin North Am; 2004 May; 30(2):381-91, viii. PubMed ID: 15172047
[TBL] [Abstract][Full Text] [Related]
13. Drug Insight: abatacept for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Nat Clin Pract Rheumatol; 2006 Dec; 2(12):654-60. PubMed ID: 17133250
[TBL] [Abstract][Full Text] [Related]
14. T-cell-targeted therapies in rheumatoid arthritis.
Weyand CM; Goronzy JJ
Nat Clin Pract Rheumatol; 2006 Apr; 2(4):201-10. PubMed ID: 16932686
[TBL] [Abstract][Full Text] [Related]
15. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation.
Konsta M; Rallis E; Karameris A; Stratigos A; Sfikakis PP; Iliopoulos A
J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):257-8. PubMed ID: 22280512
[No Abstract] [Full Text] [Related]
16. Disturbances in B- and T-cell homeostasis in rheumatoid arthritis: suggested relationships with antigen-driven immune responses.
Fekete A; Soos L; Szekanecz Z; Szabo Z; Szodoray P; Barath S; Lakos G
J Autoimmun; 2007; 29(2-3):154-63. PubMed ID: 17826949
[TBL] [Abstract][Full Text] [Related]
17. Co-stimulatory blockade as therapy for rheumatoid arthritis.
Mackie SL; Vital EM; Ponchel F; Emery P
Curr Rheumatol Rep; 2005 Oct; 7(5):400-6. PubMed ID: 16174492
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets.
Gizinski AM; Fox DA; Sarkar S
Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):463-77. PubMed ID: 20732645
[TBL] [Abstract][Full Text] [Related]
19. Abatacept mechanism of action: concordance with its clinical profile.
Herrero-Beaumont G; Martínez Calatrava MJ; Castañeda S
Reumatol Clin; 2012; 8(2):78-83. PubMed ID: 22104048
[TBL] [Abstract][Full Text] [Related]
20. Targeting of cells involved in the pathogenesis of rheumatoid arthritis.
Panayi GS
Rheumatology (Oxford); 1999 Nov; 38 Suppl 2():8-10. PubMed ID: 10646482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
